CCL22 and Alzheimer disease: According to improvement of clinical symptoms, dupilumab has been significantly demonstrated to reduce the elevated expression of Th2 signatures such as IL-13, IL-31, Chemokine (C-C motif) ligand (CCL)17, CCL18, CCL22 and CCL26 in the blood and lesional skin of AD [66,67].